# FX-111

Source: https://onco.cc/drugs/fx-111/  
OnCo record `fx-111` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FX-111 is an experimental protein degrader from Flare Therapeutics, in phase 1 trials for metastatic castration-resistant prostate cancer.

## Summary

FX-111 is a degrader (the company describes its molecules as small molecules) from Flare Therapeutics. A selective degrader of the active, hormone-bound form of the androgen receptor, which the company calls AR ON. The phase 1 study NCT07719361, which started in July 2026, is recruiting. Whether it works in people has not been established.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Code: FX-111
- Modality: Degrader (the company describes its molecules as small molecules)
- Mechanism: A selective degrader of the active, hormone-bound form of the androgen receptor, which the company calls AR ON.

## Sources

- Flare Therapeutics FX-111: https://www.flaretx.com/pipeline/fx-111/
- ClinicalTrials.gov NCT07719361: https://clinicaltrials.gov/study/NCT07719361

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/)
- companies: [Flare Therapeutics](https://onco.cc/companies/flare-therapeutics/)
- trials: [A Study in Patients With Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct07719361/)

---
JSON: https://onco.cc/api/v1/entities/fx-111.json